Vesicular Stomatitis Virus G Pseudotyped Retrovector Mediates Effective in Vivo Suicide Gene Delivery in Experimental Brain Cancer
J Galipeau, H Li, A Paquin, F Sicilia, G Karpati… - Cancer research, 1999 - AACR
J Galipeau, H Li, A Paquin, F Sicilia, G Karpati, J Nalbantoglu
Cancer research, 1999•AACRDirect in vivo tumor-targeting with “suicide” viral vectors is limited by either inefficient gene
transfer (ie, retroviral vectors) or indiscriminate transfer of a conditionally toxic gene to
surrounding nonmalignant tissue (ie, adenoviral vectors). Retrovectors pseudotyped with the
vesicular stomatitis virus G protein (VSVG) may serve as a remedy to this conundrum. These
retroviral particles differ from standard murine retroviruses by their very broad tropism and
the capacity to be concentrated by ultracentrifugation without loss of activity. We propose …
transfer (ie, retroviral vectors) or indiscriminate transfer of a conditionally toxic gene to
surrounding nonmalignant tissue (ie, adenoviral vectors). Retrovectors pseudotyped with the
vesicular stomatitis virus G protein (VSVG) may serve as a remedy to this conundrum. These
retroviral particles differ from standard murine retroviruses by their very broad tropism and
the capacity to be concentrated by ultracentrifugation without loss of activity. We propose …
Abstract
Direct in vivo tumor-targeting with “suicide” viral vectors is limited by either inefficient gene transfer (i.e., retroviral vectors) or indiscriminate transfer of a conditionally toxic gene to surrounding nonmalignant tissue (i.e., adenoviral vectors). Retrovectors pseudotyped with the vesicular stomatitis virus G protein (VSVG) may serve as a remedy to this conundrum. These retroviral particles differ from standard murine retroviruses by their very broad tropism and the capacity to be concentrated by ultracentrifugation without loss of activity. We propose that a VSVG-typed retrovector can be used for efficient and tumor-specific herpes simplex virus thymidine kinase (TK) gene delivery in vivo. To test this hypothesis, we developed a bicistronic retroviral vector that expresses TK and green fluorescence protein (pTKiGFP). The 293GPG packaging cell line was used to generate vTKiGFP retroparticles. In cytotoxicity assays, vTKiGFP-transduced human glioma cell lines were sensitized to the cytotoxic effects of gangciclovir (GCV) 10,000-fold. Subsequently, virus was concentrated by ultracentrifugation to a titer of 2.3 × 1010 cfu/ml. We tested the antitumor activity of vTKiGFP retroparticles in a rat C6 glioma model of brain cancer. Concentrated retrovector stock (9 μl volume) was injected stereotactically in preestablished intracerebral tumor. Subsequently, rats were treated with GCV for 10 days. Control rats (no GCV) had a mean survival of 38 days (range, 20–52 days). Sections performed on postmortem brain tissue revealed large tumors with evidence of high efficiency retrovector transfer and expression (as assessed by GFP fluorescence). Fluorescence was restricted to malignant tissue. In the experimental group (GCV treated), 8 of 12 remain alive and well >120 days after glioma implantation. In conclusion, vTKiGFP is very efficient at transducing human glioma cell lines in vitro and leads to significant GCV sensitization. Recombinant retroviral particles can be concentrated to titers that allow in vivo intratumoral delivery of large viral doses. The therapeutic efficiency of this reagent has been demonstrated in a preclinical model of brain cancer.
AACR
